Altria Financial Model
Consumer Goods Company Financials Example (Free Excel Download)
Altria Group, Inc. is the leading manufacturer and seller of tobacco products in the United States.
professionals from Deloitte
Used by professionals from
About this model
This model evaluates the sustainability of Altria Group's dividend and share repurchase programmes by forecasting cash flow generation against the secular decline in combustible tobacco volumes, ultimately driving a sum-of-the-parts equity valuation.
Altria Group, Inc. is the leading manufacturer and seller of tobacco products in the United States. The company operates in a highly regulated, mature industry where secular volume declines are offset by aggressive pricing power and cost management.
Business segments based on revenues net of excise taxes:
- Smokeable Products (approximately 88%): Includes cigarettes (Marlboro) and cigars (Black & Mild).
- Oral Tobacco Products (approximately 11%): Includes moist smokeless tobacco (Copenhagen, Skoal) and oral nicotine pouches (on!).
- E-Vapor Products (approximately 1%): Consists of the NJOY business acquired in 2023.
Key geographies: Substantially all revenues are generated within the United States.
Business model type: Asset-light, highly cash-generative, and heavily regulated. The model relies on brand loyalty and price inelasticity to drive margin expansion despite falling volumes.
Competitive position: Altria holds a dominant market share in the US premium cigarette category (Marlboro commands over 59% retail share) and is the market leader in moist smokeless tobacco.
Recent major events: In 2023, Altria acquired NJOY Holdings for $2.75 billion to re-enter the e-vapor market after exiting its disastrous JUUL investment. In 2024, Altria sold a portion of its equity stake in Anheuser-Busch InBev (ABI) to fund a $3.4 billion accelerated share repurchase programme. In 2025, the company recorded a $2.2 billion non-cash impairment charge related to the e-vapor segment due to illicit market competition and slower regulatory enforcement.
The downloadable Altria financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsAltria financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $26.01B | $25.10B | $24.48B | $24.02B | $23.28B |
| Gross profit | $13.99B | $14.25B | $14.28B | $14.37B | $14.54B |
| Operating income | $11.56B | $11.92B | $11.55B | $11.24B | $9.90B |
| Net income | $2.48B | $5.76B | $8.13B | $11.26B | $6.95B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Altria
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Smokeable Products
- Segment name: Smokeable Products
- Revenue driver formula: Shipment Volume (billions of units) x Gross Revenue per Thousand Units
- Historical growth rate: Revenues net of excise taxes are typically flat to down 2% annually.
- Key growth levers and headwinds: The primary headwind is a secular volume decline of 8% to 10% annually. The primary lever is price realisation, with the company typically raising prices two to three times per year.
- Pricing dynamics: Highly inelastic demand allows for consistent price increases that outpace volume declines.
- Revenue recognition notes: Recognised upon shipment to wholesalers.
- Seasonality: Relatively stable, though the third quarter often sees slight volume bumps ahead of seasonal price increases.
Oral Tobacco Products
- Segment name: Oral Tobacco Products
- Revenue driver formula: Shipment Volume (millions of cans/units) x Gross Revenue per Unit
- Historical growth rate: Low single-digit growth (1% to 3% CAGR).
- Key growth levers and headwinds: Growth is driven by the rapid adoption of oral nicotine pouches (on!), offset by mid-single-digit volume declines in traditional moist smokeless tobacco (Copenhagen, Skoal).
- Pricing dynamics: Strong pricing power in traditional moist smokeless tobacco; highly promotional and competitive pricing in the nicotine pouch category.
- Revenue recognition notes: Recognised upon shipment.
- Seasonality: Minimal seasonality.
E-Vapor Products
- Segment name: E-Vapor Products
- Revenue driver formula: Consumable Pod Volume x Price per Pod + Device Volume x Price per Device
- Historical growth rate: Highly volatile as the NJOY acquisition integrates and scales.
- Key growth levers and headwinds: Growth depends on expanding retail distribution and gaining FDA marketing authorisations. The primary headwind is the proliferation of illicit, disposable e-vapor products from international manufacturers.
- Pricing dynamics: Highly competitive, requiring significant promotional spend to drive device adoption and consumable trial.
- Revenue recognition notes: Recognised upon shipment.
- Seasonality: Minimal seasonality.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Tobacco leaf and raw materials, direct manufacturing labour, Master Settlement Agreement (MSA) payments, FDA user fees, and freight.
- Gross margin range: 68% to 70% (calculated on revenues net of excise taxes).
- Key input costs and commodity exposures: Tobacco leaf prices, packaging materials, and regulatory fees. MSA payments are a massive variable cost tied directly to cigarette shipment volumes.
- How COGS scales with revenue: COGS declines in absolute terms as volumes fall, but gross margins expand because price increases flow almost entirely to the gross profit line.
Operating Expenses
- R&D: Less than 1% of revenue. Focused on smoke-free product development and regulatory compliance (PMTA submissions to the FDA).
- SG&A: Includes marketing, advertising, promotional investments, and corporate overhead. Marketing spend is heavily restricted by law for combustible products but is elevated for the e-vapor and oral nicotine pouch segments.
- Depreciation & Amortisation: Approximately 1% to 1.5% of revenue.
- Stock-Based Compensation: Minimal relative to revenue (less than 0.5%).
- Restructuring / one-time charges: Frequent non-cash impairment charges (e.g., $2.2 billion for e-vapor in 2025) and periodic cost-saving initiative charges (e.g., the "Optimize & Accelerate" programme targeting $600 million in savings by 2029).
Margin Profile
- Gross margin: 68% to 70%.
- EBITDA margin: 58% to 60%.
- Operating margin (Adjusted OCI Margin): 60% to 62% consolidated.
- Margin trend: Expanding. The company consistently expands adjusted OCI margins by 100 to 200 basis points annually through aggressive pricing and cost reduction.
- Segment-level margins: Smokeable Products adjusted OCI margin is approximately 63.4%; Oral Tobacco Products adjusted OCI margin is approximately 67.9%.
Balance Sheet Structure
- Total assets: Approximately $36 billion to $38 billion.
- Key asset categories: Investments in equity securities (ABI, Cronos) represent a significant portion of non-operating assets.
- Goodwill & intangibles: Extremely high (over 40% of total assets), stemming from historical acquisitions (UST, NJOY) and the value of acquired trademarks.
- Working capital profile:
- Days Sales Outstanding (DSO): 10 to 15 days.
- Days Inventory Outstanding (DIO): 40 to 50 days.
- Days Payable Outstanding (DPO): 30 to 40 days.
- Net working capital as % of revenue: Consistently negative.
- Working capital dynamic: Altria operates with negative working capital. It collects cash from wholesalers quickly but pays excise taxes and MSA settlement expenses in arrears, creating a structural cash flow advantage.
- PP&E: Approximately $1.5 billion. The business is highly asset-light. Capex is primarily for maintenance and upgrading manufacturing for smoke-free products.
- Right-of-use assets / operating leases: Immaterial to the overall valuation.
Capital Expenditure & Investment
- Capex as % of revenue: 1.5% to 2.0% of revenues net of excise taxes.
- Maintenance capex vs. growth capex: Approximately 60% maintenance, 40% growth (focused on smoke-free manufacturing and import/export capabilities).
- Major capex programmes underway: Investments in contract manufacturing and regulatory preparations for the national rollout of on! PLUS.
- Capitalised software / development costs: Immaterial.
- M&A pattern: Transformational but infrequent. The company attempts to buy growth in adjacent categories (e.g., the $12.8 billion JUUL investment which was written off, and the $2.75 billion NJOY acquisition).
- Typical acquisition multiple paid: Historically paid very high multiples for growth assets (e.g., NJOY was acquired for approximately 15x to 20x forward revenue).
Debt & Capital Structure
- Total debt: Approximately $24 billion to $25 billion.
- Debt/EBITDA ratio: Target is approximately 2.0x.
- Credit rating: BBB (Standard & Poor's) / Baa2 (Moody's).
- Key debt instruments: Primarily long-term unsecured senior notes.
- Maturity profile: Well-laddered with average maturities exceeding 10 years.
- Interest rate profile: Over 90% fixed rate. Weighted average coupon is approximately 4.0% to 4.5%.
- Covenants: Standard investment-grade covenants; no restrictive financial maintenance covenants that pose near-term risk.
- Share repurchase programme: Highly active. The company repurchased $1 billion in shares in 2025 and has a $2 billion authorisation expiring in December 2026.
- Dividend policy: Target payout ratio is approximately 80% of adjusted diluted EPS. The dividend yield typically ranges from 7% to 9%, with mid-single-digit annual growth.
Cash Flow Characteristics
- Operating cash flow conversion: OCF / Net Income is frequently greater than 1.2x due to massive non-cash impairment charges and depreciation.
- Free cash flow margin: Approximately 40% to 45% of revenues net of excise taxes.
- Major non-cash items: Impairment of goodwill/intangibles (e.g., $2.2 billion in 2025), equity earnings from ABI, and deferred income taxes.
- Working capital cash flow impact: Generally a slight source of cash, though declining volumes mean the negative working capital float shrinks slightly each year.
- Capex intensity: Extremely low (projected at $300 million to $375 million for 2026).
- Cash tax rate vs. GAAP effective tax rate: Cash taxes closely track the adjusted effective tax rate of 22.5% to 23.5%.
Sheet Structure
- Assumptions: Hardcoded inputs for macroeconomic drivers, segment volumes, pricing growth, margin targets, tax rates, and capital return policies.
- Revenue & Volume: Detailed build of shipment volumes and pricing for Smokeable, Oral, and E-Vapor. Calculates Gross Revenues, deducts Excise Taxes, and outputs Revenues Net of Excise Taxes.
- Operating Income (OCI): Segment-level profitability. Calculates Adjusted Operating Companies Income (OCI) by applying segment margin assumptions to net revenues. Deducts unallocated corporate expenses.
- Income Statement: Consolidated P&L from Net Revenues down to Net Income and EPS. Includes special items, impairment charges, and equity earnings from ABI.
- Balance Sheet: Standard asset, liability, and equity lines. Highlights the massive intangible asset base and negative working capital position.
- Working Capital Schedule: Calculates Receivables, Inventories, Payables, and Accrued Settlement Charges (MSA) based on days outstanding and volume drivers.
- Debt & Interest Schedule: Tranches of senior notes, interest expense calculation, and debt maturity ladder.
- Cash Flow Statement: Bridges Net Income to OCF, CFI, and CFF. Tracks the massive dividend payments and share repurchases.
- Equity Investments: Tracks the carrying value and equity earnings from the ABI and Cronos stakes.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, terminal value (using a very low or negative terminal growth rate), and implied share price.
- Dividend & Returns Analysis: Tracks the payout ratio against adjusted EPS to validate the sustainability of the dividend yield.
Key Financial Relationships
- `Smokeable Gross Revenue = Smokeable Shipment Volume x Gross Revenue per Thousand Units / 1000`
- `Smokeable Net Revenue = Smokeable Gross Revenue - Smokeable Excise Taxes`
- `Oral Tobacco Net Revenue = Oral Tobacco Volume x Net Revenue per Unit`
- `Consolidated Revenues Net of Excise Taxes = Smokeable Net Revenue + Oral Tobacco Net Revenue + E-Vapor Net Revenue`
- `Smokeable Adjusted OCI = Smokeable Net Revenue x Smokeable Adjusted OCI Margin`
- `Oral Tobacco Adjusted OCI = Oral Tobacco Net Revenue x Oral Tobacco Adjusted OCI Margin`
- `Consolidated Adjusted OCI = Smokeable Adjusted OCI + Oral Tobacco Adjusted OCI + E-Vapor Adjusted OCI - General Corporate Expenses`
- `MSA Expense = Smokeable Shipment Volume x MSA Rate per Unit`
- `Adjusted Net Earnings = (Consolidated Adjusted OCI - Interest Expense + Equity Earnings from Investments) x (1 - Adjusted Effective Tax Rate)`
- `Adjusted Diluted EPS = Adjusted Net Earnings / Diluted Weighted Average Shares Outstanding`
- `Dividends Paid = Diluted Weighted Average Shares Outstanding x Annual Dividend per Share`
- `Ending Shares Outstanding = Beginning Shares Outstanding - (Share Repurchase Spend / Average Share Price)`
Cross-Sheet Dependencies
- The Revenue & Volume sheet is the foundation. It feeds Revenues Net of Excise Taxes to the Operating Income (OCI) sheet and the Income Statement.
- The Operating Income (OCI) sheet feeds EBIT/Operating Income to the Income Statement and the DCF Valuation.
- The Income Statement generates Net Income, which feeds the top of the Cash Flow Statement and Retained Earnings on the Balance Sheet.
- The Working Capital Schedule relies on Revenues and COGS from the Income Statement and feeds the changes in working capital to the Cash Flow Statement.
- The Cash Flow Statement calculates ending cash, which links to the Balance Sheet. It also calculates share repurchases, which feeds the share count reduction in the Income Statement (creating a circularity if share price is dynamically linked to EPS, so share price should be hardcoded or lagged).
- The Debt & Interest Schedule feeds Interest Expense to the Income Statement, creating a standard circularity if revolving debt is used to fund cash shortfalls (though Altria typically funds from free cash flow).
Sign Convention
- Revenues, volumes, and margins are entered and displayed as positive numbers.
- Expenses (COGS, SG&A, Interest Expense) are entered as positive numbers in the assumptions but subtracted in the Income Statement formulas.
- On the Cash Flow Statement, cash inflows are positive and cash outflows (capex, dividends, share repurchases, debt paydown) are negative.
- Working capital changes: An increase in an asset is a negative cash flow; an increase in a liability is a positive cash flow.
Things Most Likely to Go Wrong
- Modelling revenue based on Gross Revenue instead of Revenues Net of Excise Taxes. Margins and growth metrics must always be calculated on the net figure, as excise taxes are a massive pass-through cost.
- Underestimating the secular volume decline in the Smokeable segment. Cigarette volumes decline by 8% to 10% annually; the model must rely on aggressive price increases to keep revenue flat.
- Failing to account for the Master Settlement Agreement (MSA) payments. These are volume-driven and sit in COGS, creating a unique dynamic where COGS falls significantly as volumes decline.
- Ignoring the gap between GAAP EPS and Adjusted EPS. GAAP earnings are frequently distorted by massive non-cash impairments (like the $2.2 billion e-vapor charge in 2025) and mark-to-market adjustments on the ABI stake. The model must forecast Adjusted EPS to determine dividend sustainability.
- Miscalculating the dividend burden. Altria pays out approximately 80% of its adjusted earnings. If the model does not accurately forecast share repurchases, the share count will remain too high, causing the total dividend cash outlay to exceed free cash flow.
- Assuming positive working capital. Altria operates with negative working capital. If the builder models standard positive DSO/DIO/DPO relationships without checking the net position, cash flow will be materially understated.
- Overestimating capital expenditures. This is an asset-light business. Capex should not exceed $300 million to $400 million annually.
- Failing to separate the equity earnings of ABI from operating income. ABI earnings sit below the operating line and do not generate proportional cash flow (only the dividends received from ABI generate cash).
Validation Checks
- Revenues Net of Excise Taxes should remain relatively flat (between $19.5 billion and $20.5 billion) as price increases offset volume declines.
- Smokeable Adjusted OCI Margin must be in the 62% to 64% range. Flag if it drops below 60%.
- Consolidated Free Cash Flow should consistently exceed $8.0 billion annually.
- The Dividend Payout Ratio must remain between 75% and 85% of Adjusted EPS.
- Debt to EBITDA should remain near the company's target of 2.0x. Flag if it exceeds 2.5x.
- Capex as a percentage of Revenues Net of Excise Taxes should be strictly between 1.5% and 2.0%.
- The Balance Sheet must balance: Total Assets = Total Liabilities + Shareholders' Equity in all forecast periods.
- Adjusted Effective Tax Rate should be between 22.5% and 23.5% based on management guidance.
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Smokeable Volume Growth | -9.0 | % | Blended average of recent 8% to 10% annual secular declines. |
| Smokeable Net Price Growth | 8.5 | % | Required to offset volume declines and maintain flat net revenues. |
| Oral Tobacco Volume Growth | -2.0 | % | Growth in on! offset by declines in traditional MST. |
| Oral Tobacco Net Price Growth | 4.0 | % | Steady pricing power in traditional smokeless products. |
| Smokeable Adjusted OCI Margin | 63.4 | % | Actual reported margin for FY2025. |
| Oral Tobacco Adjusted OCI Margin | 67.9 | % | Actual reported margin for FY2025. |
| Consolidated Capex | 350 | $ Millions | Midpoint of management's 2026 guidance ($300M - $375M). |
| Adjusted Effective Tax Rate | 23.0 | % | Midpoint of management's 2026 guidance (22.5% - 23.5%). |
| Annual Share Repurchases | 1,000 | $ Millions | Matches the 2025 actual run-rate and remaining authorisation. |
| Target Dividend Payout Ratio | 80.0 | % | Historical management target against Adjusted EPS. |
| Cost of Debt (Interest Rate) | 4.5 | % | Approximate weighted average coupon on existing senior notes. |
| Terminal Growth Rate | -1.0 | % | Reflects the terminal secular decline of the combustible tobacco industry. |
| WACC | 8.5 | % | Standard discount rate for a mature, high-yield consumer staples equity. |
Data Sources & Benchmarks
- SEC EDGAR: Altria Group, Inc. (Ticker: MO) 10-K and 10-Q filings.
- Investor Relations: altria.com/investors for earnings releases, CAGNY presentations, and quarterly metrics.
- Key Peers for Benchmarking: Philip Morris International (PM), British American Tobacco (BTI), Imperial Brands (IMBBY).
- Industry Data Sources: NielsenIQ (for retail market share and convenience store volume data), FDA Center for Tobacco Products (for PMTA authorisation tracking).
- Consensus Estimates: Bloomberg or FactSet for forward EPS and revenue estimates to validate model outputs against the street.
Sources
- Altria Group, Inc. Form 10-K for the fiscal year ended December 31, 2024 (SEC EDGAR).
- Altria Group, Inc. Q4 and Full-Year 2025 Earnings Release and Investor Presentation (January 29, 2026).
- Altria Group, Inc. Q3 2025 Earnings Release (October 30, 2025).
- Altria Group, Inc. 2026 Consumer Analyst Group of New York (CAGNY) Conference Presentation.
Do more with the Altria model
Frequently asked
What products does Altria Group, Inc. manufacture and sell?+
Altria Group is the leading manufacturer and seller of tobacco products in the United States. Its primary segments include Smokeable Products (cigarettes like Marlboro, cigars), Oral Tobacco Products (moist smokeless tobacco, oral nicotine pouches), and E-Vapor Products (NJOY).
How does Altria maintain its revenue despite declining tobacco volumes?+
Altria operates in a mature industry facing secular volume declines, but it offsets this through aggressive pricing power and robust cost management. The company's business model relies on strong brand loyalty and price inelasticity to drive margin expansion.
What is a key revenue growth assumption in Altria's financial model?+
A key assumption in Altria's financial model is a revenue growth rate of approximately -0.63%. This reflects the secular decline in combustible tobacco volumes, which the model aims to forecast against.
What is the primary purpose of the Altria financial model?+
The Altria financial model evaluates the sustainability of the company's dividend and share repurchase programs. It achieves this by forecasting cash flow generation against industry trends, ultimately driving a sum-of-the-parts equity valuation.
Is there a downloadable financial model available for Altria?+
Yes, an Excel financial model for Altria is available for download. This general corporate model provides a forecast horizon from fiscal year 2026 through fiscal year 2030.
How does Altria's negative working capital profile benefit its cash flow?+
Altria consistently operates with negative net working capital, which creates a structural cash flow advantage. The company collects cash from wholesalers quickly while paying excise taxes and MSA settlement expenses in arrears.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Consumer Goods Company Financial Models
Browse another company in the same sector.
Church & Dwight
Church & Dwight Co., Inc.
Colgate-Palmolive
Colgate-Palmolive is a leading global consumer products company focused on the production, distribution, and provision of household, health care, personal care, and veterinary products.
Clorox
The Clorox Company is a leading multinational manufacturer and marketer of consumer and professional products.
Deckers Brands
Deckers Brands is a global footwear, apparel, and accessories designer and distributor, best known for its powerhouse brands UGG and HOKA.
Estée Lauder Companies
The Estée Lauder Companies Inc.
Kimberly-Clark
Kimberly-Clark is a global consumer packaged goods company that manufactures and markets personal care and consumer tissue products under iconic brands such as Huggies, Kleenex, Kotex, and Scott.
Kenvue
Kenvue is the world's largest pure-play consumer health company by revenue, manufacturing and marketing a portfolio of iconic, science-backed brands including Tylenol, Neutrogena, Listerine, and Band-Aid.
Lululemon Athletica
Lululemon Athletica is a premium athletic apparel, footwear, and accessories company that designs and retails products for yoga, running, training, and other sweaty pursuits.
Explore more Consumer financial model templates.
